Norges Bank Takes $47.89 Million Position in Maximus, Inc. $MMS

Norges Bank bought a new stake in Maximus, Inc. (NYSE:MMS) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 682,143 shares of the health services provider’s stock, valued at approximately $47,886,000. Norges Bank owned 1.21% of Maximus as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd boosted its position in shares of Maximus by 17,533.3% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 529 shares of the health services provider’s stock valued at $36,000 after purchasing an additional 526 shares in the last quarter. UMB Bank n.a. lifted its stake in Maximus by 37.5% in the second quarter. UMB Bank n.a. now owns 833 shares of the health services provider’s stock valued at $58,000 after buying an additional 227 shares during the period. Bayforest Capital Ltd acquired a new position in Maximus in the second quarter valued at approximately $61,000. Parkside Financial Bank & Trust boosted its holdings in shares of Maximus by 21.7% during the 2nd quarter. Parkside Financial Bank & Trust now owns 879 shares of the health services provider’s stock worth $62,000 after buying an additional 157 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in shares of Maximus by 60.4% during the 2nd quarter. GAMMA Investing LLC now owns 1,174 shares of the health services provider’s stock worth $82,000 after buying an additional 442 shares during the period. 97.21% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Michelle F. Link sold 4,039 shares of the business’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $86.84, for a total value of $350,746.76. Following the sale, the insider owned 19,542 shares of the company’s stock, valued at $1,697,027.28. The trade was a 17.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.60% of the stock is currently owned by company insiders.

Maximus Stock Performance

NYSE MMS opened at $84.60 on Friday. The company has a fifty day moving average price of $85.43 and a 200-day moving average price of $80.37. The firm has a market cap of $4.61 billion, a price-to-earnings ratio of 15.22 and a beta of 0.56. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.64 and a quick ratio of 1.64. Maximus, Inc. has a 1 year low of $63.77 and a 1 year high of $92.50.

Maximus (NYSE:MMS) last released its earnings results on Thursday, November 20th. The health services provider reported $1.62 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.63 by ($0.01). The business had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.34 billion. Maximus had a net margin of 5.87% and a return on equity of 25.23%. The business’s revenue was up .2% on a year-over-year basis. During the same period in the prior year, the company earned $1.46 earnings per share. Maximus has set its FY 2026 guidance at 7.950-8.250 EPS. As a group, equities research analysts predict that Maximus, Inc. will post 6.15 EPS for the current fiscal year.

Maximus Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were paid a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a yield of 1.4%. The ex-dividend date was Friday, November 14th. Maximus’s payout ratio is currently 21.58%.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Zacks Research lowered shares of Maximus from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 27th. Weiss Ratings raised shares of Maximus from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $90.00.

About Maximus

Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.